Previous Article | Next Article 
J Virol. 1980 May; 34(2): 560-568
Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication.
B M Colby,
J E Shaw,
G B Elion and
J S Pagano
ABSTRACT
The effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus (EBV) DNA replication in the lymphoblastoid cell lines P3HR-1 and Raji is reported. Acyclovir at a concentration of 100 microM completely inhibited EBV DNA synthesis in superinfected Raji cells, but did not inhibit DNA synthesis in mock-infected cells. The number of EBV genome equivalents per cell in the virus-producing cell line P3HR-1 was significantly reduced by acyclovir, whereas the number of latent EBV genomes in Raji cells was not affected by the drug. In situ cytohybridization performed on untreated P3HR-1 cultures revealed the presence of relatively large amounts of EBV DNA in 15 to 20% of the cells. After a 100 microM drug treatment, no P3HR-1 cells contained levels of EBV DNA detectable by in situ cytohybridization. Indirect immunofluorescence studies demonstrated that during treatment with 100 microM acyclovir for 7 days, the percentage of P3HR-1 cells expressing viral capsid antigen was reduced. The EBV DNA remaining in P3HR-1 cells after treatment with 100 microM acyclovir (approximately 14 genomes per cell) had the properties of covalently closed circular DNA with an average molecular weight of 108 X 10(6), as determined by contour length measurements.
J Virol. 1980 May; 34(2): 560-568
This article has been cited by other articles:
-
Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S. J., Di Nicola, M., Gianni, A. M., Klein, C., Horwitz, S., Faller, D. V.
(2007). A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood
109: 2571-2578
[Abstract]
[Full Text]
-
Gershburg, E., Pagano, J. S.
(2005). Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother
56: 277-281
[Abstract]
[Full Text]
-
Bech, E., Lycke, J., Gadeberg, P., Hansen, H.J., Malmestrom, C., Andersen, O., Christensen, T., Ekholm, S., Haahr, S., Hollsberg, P., Bergstrom, T., Svennerholm, B., Jakobsen, J.
(2002). A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology
58: 31-36
[Abstract]
[Full Text]
-
Kira, T., Grill, S. P., Dutschman, G. E., Lin, J.-S., Qu, F., Choi, Y., Chu, C. K., Cheng, Y.-C.
(2000). Anti-Epstein-Barr Virus (EBV) Activity of beta -L-5-Iododioxolane Uracil Is Dependent on EBV Thymidine Kinase. Antimicrob. Agents Chemother.
44: 3278-3284
[Abstract]
[Full Text]
-
Wandinger, K.-P., Jabs, W., Siekhaus, A., Bubel, S., Trillenberg, P., Wagner, H.-J., Wessel, K., Kirchner, H., Hennig, H.
(2000). Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology
55: 178-184
[Abstract]
[Full Text]
-
Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K., Pagano, J. S.
(1999). Inhibition of Epstein-Barr Virus Replication by a Benzimidazole L-Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-beta -L-Ribofuranosyl-1H-Benzimidazole. J. Virol.
73: 7271-7277
[Abstract]
[Full Text]
-
Haque, T., Amlot, P. L., Helling, N., Thomas, J. A., Sweny, P., Rolles, K., Burroughs, A. K., Prentice, H. G., Crawford, D. H.
(1998). Reconstitution of EBV-Specific T Cell Immunity in Solid Organ Transplant Recipients. J. Immunol.
160: 6204-6209
[Abstract]
[Full Text]
-
Lin, J., Smith, M., Cheng, Y., Pagano, J.
(1983). Epstein-Barr virus: inhibition of replication by three new drugs. Science
221: 578-579
[Abstract]
Copyright © 1980 by the American Society for Microbiology. All rights reserved.